Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Risk genes beyond APOE

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The Alzheimer A beta amyloid peptide (A beta) is the principal proteinaceous component of amyloid associated with Alzheimer disease (AD). We have determined the relative abundance of A beta structural variants present in amyloid from brains of 10 individuals with sporadic AD, 2 individuals with familial AD carrying specific mutations in the Alzheimer amyloid precursor protein gene, and 5 nondemented elderly controls. A procedure of isolation based on the extreme insolubility of A beta amyloid was used.

What this study adds

Evidence grade: Low

This study measured the relative amounts of different A beta variants in amyloid from the brains of people with sporadic Alzheimer's disease, familial Alzheimer's disease, and nondemented elderly controls. It describes the composition of amyloid but does not test or suggest any treatment, cure, or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., et al. (1994). Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.91.18.8378

Vancouver

Näslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proceedings of the National Academy of Sciences of the United States of America. 1994. doi:10.1073/pnas.91.18.8378. PMID: 8078890.

BibTeX

@article{naslund1994-8078890,
  author  = {Näslund, J. and Schierhorn, A. and Hellman, U. and Lannfelt, L. and Roses, A. D. and Tjernberg, L. O. and Silberring, J. and Gandy, S. E. and others},
  title   = {{Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging}},
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  year    = {1994},
  doi     = {10.1073/pnas.91.18.8378},
  pmid    = {8078890},
  url     = {https://doi.org/10.1073/pnas.91.18.8378}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study measured the relative amounts of different A beta variants in amyloid from the brains of people with sporadic Alzheimer's disease, familial Alzheimer's disease, and nondemented elderly controls. It describes the composition of amyloid but does not test or suggest any treatment, cure, or prevention.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Proceedings of the National Academy of Sciences of the United States of America)
Journal's citation record 4 / 4 Proceedings of the National Academy of Sciences: journal h-index 1,167 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1994 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 471 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 13.9 citations a year over 34 year(s) since 1994
Impact for its field and year 3 / 6 Cited 6.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 2 / 4 Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Paul Greengard: h-index 206 (OpenAlex, whole career)
Institution's track record 1 / 3 Karolinska Institutet: institution h-index 1,477 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 8078890)
Free to read 0 / 2 Behind a paywall — scores zero
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Risk genes beyond APOE from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →